MedTrace Logo

Evaluation of the Levels of Salivary Paxillin Oral Premalignant and Malignant Lesions

NCT06154551 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2023-12-04

No results posted yet for this study

Summary

This investigation was carried out to analyze and compare the salivary paxillin levels between oral premalignant and malignant lesions (OPMLs), OSCC and the healthy controls in order to assess its potential role as a biomarker of oral cancer aiming for early diagnosis and better prognosis of OSCC.

Methods: Forty-five patients, ranging in age from thirty to seventy-five, were divided into three groups: fifteen patients with OPMLs (lichen planus, leukoplakia), fifteen patients with OSCC, and fifteen controls who were in general well. Paxillin was identified in saliva samples by using an ELISA kit.

Conditions

  • Comparison of Salivary Paxillin Levels in OPMLs and OSCC to Healthy Subjects

Interventions

DIAGNOSTIC_TEST

Paxillin biomarker

Paxillin used as a salivary biomarker

Sponsors & Collaborators

  • Olfat Shaker

    collaborator UNKNOWN

  • Cairo University

    lead OTHER

Principal Investigators

  • Yasmine Ramadan · Cairo University

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-29
Primary Completion
2023-06-20
Completion
2023-11-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06154551 on ClinicalTrials.gov